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ABSTRACT 
 
HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes:  
An Exploratory Association Study 
 
by 
Derek Edward Murrell 
As HIV is now primarily a chronic condition, treatment is given life-long with changes as 
necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be 
useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the 
four currently available HIV integrase strand transfer inhibitors (INSTIs), raltegravir, 
elvitegravir, and dolutegravir, are widely utilized antiretrovirals in the USA and exhibit 
variations in outcomes among subjects. To interrogate differences among subjects receiving 
these drugs, we investigated the association of several single nucleotide polymorphisms (SNPs) 
with drug exposure, clinical outcomes, and subject-reported adverse events. HIV+ adults (≥18 
years old) receiving an INSTI regimen were recruited (n=88). Subject genotypes were evaluated 
using an iPLEX PGx Panel. Genetic variations within our population, underwent multiple 
regression with covariates [age, sex, BMI, regimen duration, and baseline variables (as required) 
along with specific regimen in the comprehensive group] to detect significant (p<0.05) 
associations with concentration and selected clinical data. Additionally, multiple logistic 
regression, with the previous covariates, tested for association with binary traits including central 
nervous system-related (abnormal dream, anxiety, fatigue, headache, and insomnia) and 
gastrointestinal-related (diarrhea and nausea) adverse events. With a median age of 52.5 years 
(IQR 45.7-57.2) being predominately Caucasian (88.6%) and male (86.4%), we found an 
association (p=0.028) between abnormal dream occurrence and specific INSTI regimen with the 
raltegravir grouping presenting a higher frequency. This exploratory study also discovered 
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several SNP-outcome associations when using INSTIs. Although these SNPs were found to have 
a role in predicting segments of adverse effect profiles, the clinical significance of these findings 
remains to be determined. Larger studies will be needed to confirm these exploratory findings 
with functional studies to understand pathogeneses. In conclusion, the associations found in this 
study strengthen the need for further assessment, within the HIV+ population, of factors 
contributing to unfavorable subject outcomes.  
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CHAPTER 1 
INTRODUCTION 
After nearly four decades, human immunodeficiency virus (HIV) remains a high priority 
in biomedical research with thousands of new infections occurring each day adding to the 
upward of 36 million HIV positive individuals the world over ("HIV Data and Statistics," 2017). 
Current drug treatments are highly effective in reducing plasma HIV viral load; however, several 
factors may interact to alter the efficacy and tolerability of antiretrovirals (Gandhi et al., 2012; 
Hewitt, 2002). Because HIV positive individuals are living relatively longer and healthier lives 
due to improved treatment, the frequency and severity of side effects may increase with age-
related physiological changes and the increased probability of comorbidities (Dumond et al., 
2013). In addition, variations in the genetic make-up of an individual may also alter the behavior 
of some drugs, resulting in differences in efficacy and toxicity (Wyatt, Pettit, & Harirforoosh, 
2012). Compounded with the current absence of a cure, treatment regimens must be continued 
lifelong. Thus, the availability of safe and continually effective treatment options is an increasing 
concern to the HIV health care provider. 
HIV: Overview 
Transmission 
HIV is typically contracted sexually, parenterally, or vertically (Shaw & Hunter, 2012). 
Sexual contact involving the exchange of bodily fluids, such as semen or vaginal secretions, 
possesses an increased probability of infection. Parenteral transmission, occurring through the 
sharing of virally contaminated needles, is common among those who abuse intravenous drugs. 
Vertical transmission occurs when the virus travels from mother to child through contact with 
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maternal blood at birth, via breast feeding, or in utero. Other transmission avenues that are 
possible, but less probable include accidental needle sticks, mucocutaneous exposure, or 
contaminated blood/tissue transplants (DiPiro, 2011; Longo, 2012). 
Replication 
As a single-stranded RNA virus (two copies per retrovirus), HIV must enter a host cell to 
replicate (Metifiot, Marchand, & Pommier, 2013). Infection occurs when HIV interacts with 
CD4 receptors present on a host cell, primarily CD4+ T-cells, then fuses with the cell. The viral 
coat is removed inside the cell revealing the viral RNA, which is reverse transcribed by a viral 
enzyme, reverse transcriptase (RT), to complementary DNA (cDNA). Viral double-stranded 
DNA (dsDNA), created from cDNA via host polymerases, is processed then translocated into the 
cellular nucleus prior to integration into the host genome via HIV integrase (IN). This integration 
creates a provirus which evades host immune responses through latency (Lampiris, 2012); 
however, upon activation, the viral genome is expressed, leading to protein translation and 
processing by viral proteases. Viral RNA, enzymes, and coat are then organized into mature 
viruses, which bud from the host cell (Metifiot et al., 2013). Disease progression and 
antiretroviral therapy efficacy may be determined using HIV RNA concentration in plasma and 
CD4+ cell count as biomarkers (DeJesus et al., 2012; Sax et al., 2012; Zolopa et al., 2013). 
Antiretroviral Therapy 
Currently, there is no effective vaccine against or method of cure for HIV infection; 
however, numerous antiretroviral medicines have been devised to combat the progression of HIV 
infection into acquired immune deficiency syndrome (AIDS). Because no drug has proven to be 
exceedingly effective individually and the HIV genome is capable of rapidly developing drug 
resistance, the use of multiple drug classes each addressing a different aspect of HIV infection 
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and replication is preferred. Thus highly active antiretroviral therapy (HAART), consisting of 
one or more members of the following drug classes: protease inhibitor (PI), nucleoside and 
nucleos(t)ide reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase 
inhibitor (NNRTI), entry inhibitor, and/or integrase strand-transfer inhibitor (INSTI), has 
become routine in the treatment of HIV (Metifiot, Marchand, Maddali, & Pommier, 2010; Olin, 
Spooner, & Klibanov, 2012; Pavlos & Phillips, 2012; Zanger & Klein, 2013). Strict compliance 
with medication regimens is required to avoid viral mutations which can render individual or 
even classes of antiretrovirals ineffective. This study focused on three of the four currently 
available INSTIs which were and remain frontline regimens (Tsiang et al., 2016). Bictegravir 
was not included due to the lack of usage and clinical experience at the commencement of this 
observational study. 
Integrase Strand Transfer Inhibitors (INSTIs) 
Mechanism of Action 
Following reverse transcription of viral RNA by reverse transcriptase and synthesis of 
dsDNA by cellular enzymes, viral IN recognizes the newly synthesized dsDNA and performs a 
function known as 3’-processing (Dayam et al., 2008). Two bases, G and T, are removed from 
both 3’ ends of the viral dsDNA then the pre-integration complex (PIC), consisting of processed 
dsDNA, IN, and other necessary cofactors, moves to the nucleus. The dsDNA is initially 
integrated into the host DNA through IN then completed via host DNA repair enzymes (Liao, 
Marchand, Burke, Pommier, & Nicklaus, 2010). 
IN consists of three subunits, an N-terminal domain, a catalytic domain, and a C-terminal 
domain. The DNA binding function of the catalytic domain is targeted by INSTIs (Lampiris, 
2012). Mg2+ ions are believed to be essential for the catalytic capabilities of IN as well as the 
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formation of the PIC through dsDNA binding (Liao et al., 2010). INSTIs chelate the Mg2+ ions at 
the active catalytic site of IN, preventing 3’-processing and dsDNA covalent binding (Pommier 
& Marchand, 2012). Without the interaction between IN and dsDNA, viral DNA is unable to 
integrate into the host genome and replication is not possible (Correll & Klibanov, 2008). 
Raltegravir  
Merck introduced raltegravir, formerly MK-0518, as the first FDA-approved INSTI in 
October 2007 under the brand name of Isentress for adults then (December 2011) approved for 
use in pediatric subjects (Hajimahdi & Zarghi, 2016; Traynor, 2007). Discovered while 
searching for a HCV polymerase inhibitor, raltegravir is a derivative of dihydroxypyrimidine 
carboxamide (Hajimahdi & Zarghi, 2016). 
Although primarily administered twice daily as a film-coated 400 mg tablet, single 800 or 
1200 mg doses have also been examined (Cahn et al., 2017; Eron et al., 2011). The 1200 mg 
dose was recently approved by the FDA ("Isentress Prescribing Information," 2017). 
Administration is not dependent upon the presence of food and pharmacokinetic boosting is not 
necessary. In the fasted state, the time to reach maximum plasma concentration, or the Cmax, 
(Tmax) is reached in 3 hours with a half-life of nearly 9 hours (Brainard, Wenning, Stone, 
Wagner, & Iwamoto, 2011); however, raltegravir pharmacokinetics have been shown to be 
variable within and between subjects (Rizk et al., 2012). Protein binding appears to be 
approximately 83% with 51% of the drug being excreted unchanged in feces ("Isentress 
Prescribing Information," 2017). Raltegravir undergoes glucuronidation via uridine diphosphate 
glucuronosyltransferase (UGT) 1A1 (UGT1A1). Raltegravir is dosed with various antiretroviral 
backbone regimens, such as tenofovir disoproxil fumarate/emtricitabine or tenofovir 
alafenamide/emtricitabine. 
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Several clinical studies have shown the utility of raltegravir. The double-blind 
STARTMRK trial has demonstrated raltegravir efficacy (over five years) and superiority over 
efavirenz/emtricitabine/tenofovir disoproxil fumarate (Lennox et al., 2009; Rockstroh et al., 
2011). The proportion of virally suppressed individuals with HIV RNA < 50 copies/ml at week 
240 was 71% vs. 61% for raltegravir and efavirenz regimens, respectively. Although the 
QDMRK study, in which groups received the tenofovir disoproxil fumarate/emtricitabine 
background, showed that raltegravir (800 mg; once-daily) did not reach non-inferiority compared 
to raltegravir (400; twice-daily) at 48 weeks, over 83% of the once-daily group achieved viral 
suppression (Eron et al., 2011). Several reviews have provided further detail on each of the 
studies concerning INSTIs (Raffi & Wainberg, 2012). 
Elvitegravir  
Elvitegravir, formally known as JTK-303 and GS-9137, is a hydroxyquinolone 
(quinolone-3-car1boxylic acid derivative) which interferes with HIV viral integration (Correll & 
Klibanov, 2008; Hajimahdi & Zarghi, 2016). Although discovered by Japan Tobacco, Gilead 
Sciences currently produces two treatment options, Stribild and its younger sibling Genvoya, 
which were approved for use in the United States by the FDA in August 2012 and November 
2015, respectively ("Genvoya Prescribing Information," 2017). Both combination regimens 
contain elvitegravir, cobicistat, and emtricitabine; while differing in the tenofovir prodrug (D. E. 
Murrell, Harirforoosh, S, 2016; Sax et al., 2015). Elvitegravir has also been approved for 
independent administration as Vitekta by the FDA and European Commission. 
Elvitegravir is administered orally in tablet form with the presence of food playing a 
significant role in bioavailability (Lampiris, 2012; Olin et al., 2012). When co-formulated in 
Stribild, elvitegravir peak drug concentrations are achieved within 4 hours post dose and 
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absorption is elevated when administered with food (light meal, increased 34% vs fasting; high 
fat meal, increased 87% vs. fasting). Plasma protein binding is high for elvitegravir (98-99%) 
and nearly 95% of the drug is excreted in feces (Ramanathan, Mathias, German, & Kearney, 
2011).  
Phase I metabolism of elvitegravir is performed by cytochrome P450 (CYP) 3A4 
(CYP3A4); the drug can also undergo glucuronidation by UGT1A1/3 (Adams, Greener, & 
Kashuba, 2012; Olin et al., 2012; Ramanathan, Kakuda, Mack, West, & Kearney, 2008). As an 
inducer of CYP3A4 and CYP2C9, which diminishes the half-life of substrates metabolized by 
these enzymes, elvitegravir has a relatively short half-life of 3 hrs (Adams et al., 2012). Rather 
than increasing dosage to achieve appropriate systemic exposure, elvitegravir is administered 
with a pharmaco-enhancer which decreases drug metabolism (Olin et al., 2012).  
Originally paired with ritonavir, elvitegravir is now partnered with a more precise 
inhibitor, cobicistat. Co-formulation with cobicistat, which triples the half-life of elvitegravir to 9 
hrs, is beneficial in helping to prevent the development of drug resistance (Adams et al., 2012). 
Also as elvitegravir is not altered by most NRTIs, co-formulation with emtricitabine and 
tenofovir disoproxil fumarate is possible (Correll & Klibanov, 2008). 
Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine has been documented to be 
non-inferior to efavirenz/tenofovir disoproxil fumarate/emtricitabine and to atazanavir (a 
PI)/ritonavir+/tenofovir disoproxil fumarate/emtricitabine as evaluated by the proportion of 
formerly drug-naïve patients demonstrating viral load suppression to below 50 copies RNA/ml 
after 48 weeks of treatment (DeJesus et al., 2012; Sax et al., 2012). 
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Dolutegravir  
ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer, developed 
dolutegravir, a tricyclic carbamoyl pyridine, and introduced the drug as Tivicay (50 mg DTG) in 
August 2013 (Ballantyne & Perry, 2013; Hajimahdi & Zarghi, 2016). One year later, Triumeq, a 
combination of dolutegravir (50 mg), abacavir (600 mg), and lamivudine (300 mg), also received 
FDA approval (Gohil, 2014). Due to the inclusion of abacavir, this single tablet regimen is only 
available for HLA-B*5701 negative individuals (Greig & Deeks, 2015).  
Dolutegravir was thought to be an improvement upon raltegravir, in terms of dosing 
schedule (prior to the 1200 mg once-daily dose) ("Isentress Prescribing Information," 2017), and 
elvitegravir, in terms of boosting (Molina et al., 2015). Although food does not seem to have a 
clinically significant effect on drug absorption, meal fat content (low, moderate, or high) has 
been shown to increase the area under the plasma concentration time curve (33%, 41%, and 66%, 
respectively compared to fasting) ("Tivicay Prescribing Information," 2017). Apparent volume 
of distribution was determined to be approximately 17.4 L with protein binding of nearly 99% 
when administered as Triumeq (Greig & Deeks, 2015). Dolutegravir is principally metabolized 
by UGT1A1; however, CYP3A enzymes produce a minor metabolite as well (Castellino et al., 
2013). A half-life of 14 hours has been seen with dolutegravir (Min et al., 2010). Unchanged 
drug is excreted 53% in the feces with very little (<1%) in the urine; however, 31% of 
metabolized dolutegravir is found in the urine ("Tivicay Prescribing Information," 2017). 
Dolutegravir was also found to distribute into the cerebrospinal fluid (Greig & Deeks, 2015). 
A meta-analysis of four randomized controlled trials comprised of treatment-naïve 
individuals performed by Jiang et al. found that dolutegravir regimens were superior to efavirenz 
(an NNRTI) and raltegravir based regiments in terms of safety and efficacy (Jiang et al., 2016). 
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Nausea and headache were the most frequent adverse events associated with dolutegravir. When 
dosed with dual NRTI regimens (abacavir/lamivudine or tenofovir disoproxil 
fumarate/emtricitabine) in the SINGLE study, dolutegravir was shown to be superior to 
efavirenz/tenofovir disoproxil fumarate/emtricitabine at 48 weeks of therapy (88% vs 81%, 
respective viral suppression) (Walmsley et al., 2013). Similar results were observed at 96 weeks 
(80% vs 72%, respectively) and at 144 weeks (71% vs 63%, respectively) (Greig & Deeks, 
2015). In the FLAMINGO study, dolutegravir was compared to a PI and pharmacokinetic 
booster combination, darunavir/ritonavir, (both dosed with NRTIs) for viral suppression at week 
48 (90% vs 83%, respectively) and week 96 (80% vs 68%, respectively) (Molina et al., 2015). 
Non-inferiority and superiority was conferred at 96 weeks. In the SPRING-2 study (a 
randomized double-blind double dummy study), dolutegravir+NRTI was deemed non-inferior to 
bid 400 mg raltegravir+NRTI at 48 weeks (88% vs 85% respective viral suppression) and 
showed comparable safety and tolerability at 96 weeks (81% vs 76%) (Raffi, Jaeger, et al., 2013; 
Raffi, Rachlis, et al., 2013). The SAILING study also determined that dolutegravir was not only 
non-inferior to raltegravir, but superior as well with 71% viral suppression opposed to 64% in the 
comparator group following 48 weeks of treatment (Cahn et al., 2013). 
Pharmacogenetics 
Pharmaceutical decision-making consists of several parameters; however, a relatively 
recent addition to the puzzle is the utilization of pharmacogenetics, which is the subsection of 
genetics dealing with pharmacokinetic and pharmacodynamic outcomes (Pouget, Shams, Tiwari, 
& Muller, 2014). As such, metabolic enzymes have been shown to exhibit alteration when 
genetic polymorphisms are present (Elens et al., 2013; Okubo et al., 2013; Wang, Guo, 
Wrighton, Cooke, & Sadee, 2011). Recent data suggests that CYP3A4 shows reduced activity 
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and/or expression with the presence of the CYP3A4*22 allele. Although one study did not find a 
correlation with activity (Garcia-Martin et al., 2002), another study reported a polymorphism, 
CYP3A4*1B, correlating with an increase in CYP3A4 activity (Klein & Zanger, 2013). The 
presence of CYP3A5 polymorphism has also been suggested to relate to the metabolism of 
CYP3A4 substrates (Wang & Sadee, 2012); thus CYP3A5*3 (rs776746) which yields a null 
phenotype may be important to dolutegravir and elvitegravir metabolism (Elens et al., 2013). 
CYP2D6 also has a large number of polymorphisms which influence enzyme activity (Khlifi, 
Messaoud, Rebai, & Hamza-Chaffai, 2013). In a study by Ritchie et al., a polymorphism in the 
ABCB1 gene, which encodes for p-glycoprotein (P-gp), was suggested to influence toxicity of a 
P-gp substrate such as dolutegravir (Ritchie et al., 2006; "Tivicay Prescribing Information," 
2017). In a recent study by D’Avolio et al. (D'Avolio et al., 2014), a SNP (rs4149056) in organic 
anion transport protein (OATP) 1B1, which interacts with cobicistat, was found to correlate with 
changes in ritonavir plasma concentrations.  
Specific Aims 
Because polymorphisms in drug metabolizing enzymes, transporters, and/or receptors can 
influence drug pharmacokinetics and thereby alter drug properties, we conducted an exploratory 
pharmacogenetic analysis of INSTI regimens consisting of numerous SNPs included on the 
iPLEX PGx ProPanel. We hypothesized that particular drug outcomes will be influenced by 
pharmacogenetics. This hypothesis is proposed based on the following observations. First, 
raltegravir and dolutegravir are primarily metabolized by UGT1A1 (Arab-Alameddine et al., 
2012; Castellino et al., 2013). Second, elvitegravir is metabolized by CYP3A4 (Olin et al., 
2012). Third, the expression of most enzymes is modulated by nuclear receptors (Coleman & 
Wiley InterScience (Online service), 2010), which like the expression of many drug 
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metabolizing enzymes and transporters, are influenced by genetic polymorphism (Michaud et al., 
2012). The genetic variability in the expression of enzymes and transporters may produce 
alterations in drug pharmacokinetics, and consequently drug effects (Wyatt et al., 2012). The 
following specific aims were designed to test our hypothesis: evaluate drug exposure in HIV-1 
patients, document genetic polymorphisms, collect clinical outcomes, and perform association 
analyses. 
*Portions of this chapter were previously published in European Review for Medical and 
Pharmacological Sciences (Murrell DE, Moorman JP, Harirforoosh S. Stribild: a review of 
component characteristics and combination drug efficacy. European review for medical and 
pharmacological sciences. 2015;19(5):904-14. PubMed PMID: 25807445.) 
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Abstract 
Integrase strand transfer inhibitors (INSTIs) have become integral in HIV treatment with close 
monitoring of continued efficacy and tolerability. This exploratory study evaluated 
polymorphism influence on drug exposure and tolerability. HIV+ adults (≥18yrs) receiving 
INSTI-based regimens were recruited (n=88) and genotyped with an iPLEX PGx Panel. Genetic 
variants within our population, underwent multiple regression with covariates [age, sex, BMI, 
regimen (comprehensive group), regimen duration, and baseline variables (as required)] to detect 
significant (p<0.05) association of concentration data and selected clinical data. With a median 
age of 52.5 years (IQR 45.7-57.2) being predominately Caucasian (88.6%) and male (86.4%), 
this exploratory study discovered that dolutegravir trough concentration was influenced by 
selected single nucleotide polymorphisms (SNPs). In addition, several associations were 
identified between variables and SNPs, when using INSTIs; however, clinical significance is 
unknown. These exploratory findings require confirmation in larger studies which may also 
investigate interaction mechanisms. 
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Introduction 
Over the past decade, HIV integrase strand transfer inhibitors (INSTIs) have moved to the 
frontlines of antiretroviral therapy (1). Regarding three of the four approved INSTIs 
(dolutegravir, elvitegravir, and raltegravir), each is frequently efficacious; however, variability in 
regimen tolerability may be of concern(2). Dolutegravir was thought to be an improvement upon 
raltegravir, in terms of reduced dosing frequency (prior to once-daily 1200 mg raltegravir) (3), 
and elvitegravir, in terms of boosting necessity (4); however, elevated drug concentrations can be 
problematic (5). In the case of elvitegravir, the drug concentration at the end of the dosing 
interval at steady-state (Ctrough) seems related to outcomes (6, 7). The pharmacokinetics of 
raltegravir have been shown to have intra- and inter-subject variation which may influence drug 
outcomes (8). Thus, drug exposure play an important role in the use of these regimens.  
Concurrent with the rise of the INSTIs, the field of personalized medicine has also gained 
traction in the clinical realm. One method of informing pharmaceutical decision-making is the 
integration of pharmacogenetics, the interaction of genetic information with drug 
pharmacokinetics and outcomes. Recent data suggests that cytochrome P450 3A4 (CYP3A4), a 
metabolizing enzyme of many drugs, including dolutegravir and elvitegravir, shows reduced 
activity and/or expression with the presence of the CYP3A4*22 allele (rs35599367) (9-11). 
Although a different study discovered such a correlation with activity (12), a further study 
reported a polymorphism, CYP3A4*1B (rs2740574), correlated with an increase in CYP3A4 
activity (13). The presence of CYP3A5 polymorphism has also been suggested to relate to the 
metabolism of CYP3A4 substrates, such as elvitegravir, (14); thus SNPs such as CYP3A5*3 
(rs776746) which yield a null phenotype may partially reduce metabolism (9). Drug transporters, 
such as the ATP-binding cassette transporter B1 (ABCB1), also known as p-glycoprotein, have 
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been suggested to influence toxicity of substrates (15). Dolutegravir and raltegravir, p-
glycoprotein substrates, may be adversely affected by changes in p-glycoprotein (16, 17). In this 
study, we conducted an exploratory pharmacogenetic analysis of INSTI regimens, consisting of 
numerous SNPs included on the iPLEX PGx Panel v1.0, to understand the influence of genetic 
polymorphism on overall drug exposure and clinical tolerability. 
Results 
Subject Demographics 
All HIV+ individuals receiving care at the East Tennessee State University (ETSU) 
Center of Excellence (COE) for HIV/AIDS Care (n=341) were screened for this study. Overall 
demographic characteristics, along with stratification by INSTI, are presented in Table 1. Of the 
eligible subjects (n=216), eighty-eight HIV+ individuals (86.4% male) with a median age of 52.5 
years were recruited. The primarily non-Hispanic Caucasian population presented with a mean 
BMI of 26.2. Only 3 of the 88 subjects reported a missed dose within the two weeks prior to 
sample collection. The majority (85/86) of subjects were virally suppressed (<20 RNA 
copies/mL) or had a low-level viremia (below 60 RNA copies/mL) at or near sample collection; 
while viral load data was not available for two subjects. 
 
 
 
 
 
 
 Dolutegravir 
(n=42) 
Elvitegravir 
(n=23) 
Raltegravir 
(n=23) 
Total 
(n=88) 
Age in years, median (IQR) 53.0 (42.7 - 58.5) 50.0 (42.0 - 54.5) 53.0 (50.0 - 58.5) 52.5 (45.7 – 57.2) 
Male, count (%) 37 (88.1%) 20 (87.0%) 19 (82.6%) 76 (86.4%) 
Mean Body Mass Index (SD) 24.7 ± 4.8 29.1 ± 6.6 26.0 ± 5.1 26.2 ± 5.63 
Race or ethnic group (All that apply) 
    Black 
    White 
    Other 
  
 5 
36 
2 
 
3 
19 
1 
  
 0 
23 
3 
  
 8 
78 
6 
Regimen Duration (weeks) 66.9 ± 39.0 80.8 ± 56.3 162.0 ± 77.3 95.4 ± 68.2 
 
Table 1: Subject demographics 
 
 
Pharmacogenetic Analysis 
All samples had a call rate of ≥97%. The genotyping efficiency was greater than 95% for 
all, but three SNPs (rs5030865, 77.7%; rs28371706, 57.4%; and rs1065411, 83.0%) which 
showed low yield were not included in analysis. Of the remaining 175 SNPs on the panel, 86 
were polymorphic within this population. SNPs were further excluded based on low minor allelic 
frequency below 1%. 
Drug Exposure 
Mean dolutegravir Ctrough (n=23) was determined to be 764.13±401.66 ng/mL. When 
stratified by genotype, the concentrations were associated with five SNPs as revealed in Table 
2.Two CYP2D6 SNPs (rs1065852 and rs3892097) were shown to increase dolutegravir 
concentration along with rs7294 in VKORC1.  Meanwhile, rs4149056 and rs8192709 were 
associated with decreases in dolutegravir concentration. Two of the associated SNPs, rs1065852 
and rs3892097, were in linkage disequilibrium (LD) (r2=0.850). Although the Ctrough of 
elvitegravir (n=15; 263.84±146.92 ng/mL) and raltegravir (n=6; 567.16±307.19 ng/mL) were 
determined, no SNPs showed association with elvitegravir or raltegravir concentration following 
multiple regression. 
 
 
 
 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
Dolutegravir CYP2D6 rs1065852 22 42526694 T 0.190 1.000 430.80 (149.40 — 712.20) 0.008 
 SLCOB1 rs4149056 12 21331549 C 0.095 1.000 -508.20 (-840.80 — -175.50) 0.009 
 CYP2D6 rs3892097 22 42524947 A 0.167 1.000 407.60 (102.50 — 712.60) 0.019 
 CYP2B6 rs8192709 19 41497274 T 0.060 1.000 -785.80 (-1422.00 — -149.80) 0.028 
 VKORC1 rs7294 16 31102321 A 0.452 0.984 230.30 (41.33 — 419.20) 0.030 
 
Table 2: SNPs significantly associated with drug concentration 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta 
adjusted for covariates (sex, age, BMI, and regimen duration)  
 
 
 
Hepatic Parameters 
No group had mean alkaline phosphatase (ALP) levels outside the normal range of 30-125 
U/L (18) (comprehensive group, 73.25±42.94 U/L; dolutegravir group, 69.94±24.30 U/L; 
elvitegravir group, 85.39±72.57 U/L; and raltegravir group, 66.73±24.37 U/L). The difference in 
mean ALP among the regimens was not significant (p=0.277). Table 3 shows that two SNPs 
(rs2273697 and rs737865) reached a positive significant association with ALP levels across all 
regimens. No SNPs reached multiple regression significance in the dolutegravir group. Seven 
SNPs, two of which (rs9934438 and rs9923231) being in LD (r2=1), were associated with ALP 
levels in elvitegravir-receiving individuals. The addition of minor alleles revealed increases of 
ALP in six SNPs; while minor alleles in rs7294 were negatively associated with ALP level. The 
raltegravir group had two SNPs (rs1045642 and rs17708472) yielded positive association with 
ALP levels. 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
All ABCC2 rs2273697 10 101563815 A 0.199 0.165 16.39 (2.75 — 30.03) 0.021 
 COMT rs737865 22 19930121 C 0.301 0.406 17.27 (4.90 — 29.64) 0.008 
Elvitegravir CYP2C8 rs1058930 10 96818119 G 0.043 1.000 228.60 (151.90 — 305.20) <0.001 
 VKORC1 rs9934438 16 31104878 A 0.261 0.933 72.94 (25.48 — 120.40) 0.008 
 VKORC1 rs9923231 16 31107689 T 0.261 0.933 72.94 (25.48 — 120.40) 0.008 
 ABCC2 rs2273697 10 101563815 A 0.217 0.501 62.42 (18.29 — 106.50) 0.014 
 COMT rs737865 22 19930121 C 0.196 0.329 69.59 (21.03 — 118.20) 0.013 
 VKORC1 rs7294 16 31102321 A 0.413 0.799 -55.92 (-106.70 — -5.17) 0.046 
 CYP2C9 rs1799853 10 96702047 T 0.109 1.000 91.44 (7.08 — 175.80) 0.050 
Raltegravir ABCB1 rs1045642 7 87138645 T 0.478 0.166 17.49 (3.21 — 31.78) 0.032 
 VKORC1 rs17708472 16 31105353 A 0.239 1.000 16.53 (2.90 — 30.15) 0.033 
 
Table 3: SNPs significantly associated with ALP levels 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for ALP levels 
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline ALP] 
 
 
 
The elvitegravir group (32.48±28.25 U/L) had a mean alanine aminotransferase (ALT) 
level in the upper normal range (0-40 U/L) (18); while the other groups, comprehensive, 
dolutegravir, and raltegravir, showed 26.81±20.05 U/L, 24.44±16.41 U/L, and 25.32±15.18 U/L, 
respectively. Mean ALT among the regimens did not show significant differences (p=0.285). 
Two SNPs (rs2282143 and rs1048943) were determined to have a positive association with ALT 
levels (Table 4) when all regimens were combined. There were no associated SNPs after 
dolutegravir stratification. Five SNPs, four (rs9934438, rs9923231, rs2282143, and rs1048943) 
with a positive beta and one (rs7294) with a negative beta, were associated with ALT in terms of 
elvitegravir-receiving patients. As previously noted, rs9934438 and rs9923231 were in LD along 
with rs2282143 and rs1048943 (r2=1). Additionally, raltegravir-grouped samples presented two 
associated SNPs, one negative (rs165599) and one positive (rs34059508) when analyzed for 
ALT levels. 
 
 
 
 
 
 
 
 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
ALL SLC22A1 rs2282143 6 160557643 T 0.028 0.113 29.77 (17.01 — 42.53) <0.001 
 CYP1A1 rs1048943 15 75012985 G 0.045 0.306 19.01 (7.41 — 30.61) 0.002 
Elvitegravir VKORC1 rs9934438 16 31104878 A 0.261 0.933 28.97 (11.68 — 46.25) 0.005 
 VKORC1 rs9923231 16 31107689 T 0.261 0.933 28.97 (11.68 — 46.25) 0.005 
 VKORC1 rs7294 16 31102321 A 0.413 0.799 -24.96 (-40.60 — -9.32) 0.006 
 SLC22A1 rs2282143 6 160557643 T 0.065 0.133 25.39 (6.00 — 44.77) 0.021 
 CYP1A1 rs1048943 15 75012985 G 0.065 0.133 25.39 (6.00 — 44.77) 0.021 
Raltegravir COMT rs165599 22 19956781 G 0.283 1.000 -10.65 (-18.17 — -3.13) 0.014 
 SLC22A1 rs34059508 6 160575837 A 0.065 1.000 18.34 (4.50 — 32.17) 0.020 
 
Table 4: SNPs significantly associated with ALT levels 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for ALT levels 
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline ALT levels] 
 
 
 
Mean aspartate aminotransferase (AST) levels (comprehensive group, 24.79±17.24 U/L; 
dolutegravir group, 23.49±10.38 U/L; elvitegravir group, 29.48±29.19 U/L; and raltegravir 
group, 22.32±8.48 U/L) were each within the high end of the 3-44 U/L normal range (18). No 
significant difference (p=0.307) was detected among the AST levels between the regimens. The 
four AST level-SNP associations (rs9934438, rs9923231, rs2273697, and rs4680), each being 
positive, across regimens are found in Table 5. The VKORC1 SNPs (rs934438 and rs9923231) 
were found to be in complete LD (r2=1). Dolutegravir grouping did not yield association between 
SNPs and AST values. AST levels were associated SNPs within four genes (VKORC1, CYP2C8, 
ABCC2, and CYP2E1) across elvitegravir regimens with only two SNPs in LD (r2=1). 
Raltegravir AST levels were deemed to be associated with three SNPs (rs2231142 and 
rs9282861 being positive and rs4244285 being negative). 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
ALL VKORC1 rs9934438 16 31104878 A 0.318 0.723 8.43 (2.86 — 14.00) 0.004 
 VKORC1 rs9923231 16 31107689 T 0.318 0.723 8.43 (2.86 — 14.00) 0.004 
 ABCC2 rs2273697 10 101563815 A 0.199 0.165 7.42 (1.44 — 13.39) 0.017 
 COMT rs4680 22 19951271 G 0.455 0.534 6.19 (0.82 — 11.55) 0.027 
Elvitegravir VKORC1 rs9934438 16 31104878 A 0.261 0.933 33.24 (16.68 — 49.80) 0.001 
 VKORC1 rs9923231 16 31107689 T 0.261 0.933 33.24 (16.68 — 49.80) 0.001 
 CYP2C8 rs1058930 10 96818119 G 0.043 1.000 82.01 (44.06 — 120.00) 0.001 
 ABCC2 rs2273697 10 101563815 A 0.217 0.501 30.12 (13.76 — 46.47) 0.002 
 VKORC1 rs7294 16 31102321 A 0.413 0.799 -28.99 (-47.70 — -10.28) 0.008 
 CYP2E1 rs2070673 10 135340567 A 0.239 1.000 -29.60 (-56.83 — -2.36) 0.049 
Raltegravir ABCG2 rs2231142 4 89052323 A 0.109 0.429 8.53 (1.95 — 15.12) 0.025 
 CYP2C19 rs4244285 10 96541616 A 0.174 1.000 -6.39 (-11.75 — -1.03) 0.036 
 SULT1A1 rs9282861 16 28617514 A 0.304 0.619 6.20 (0.94 — 11.46) 0.038 
 
Table 5: SNPs significantly associated with AST levels 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for AST levels 
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline AST levels] 
 
 
 
Renal Parameters 
All mean blood urea nitrogen (BUN) levels (comprehensive group, 15.10±5.11 mg/dL; 
dolutegravir group, 14.66±4.55 mg/dL; elvitegravir group, 15.00±4.32 mg/dL; and raltegravir 
group, 16.05±6.74 mg/dL) were discovered as normal (8-21 mg/dL) (18). As mean BUN among 
the regimens was similar, no significant changes (p=0.592) were found. Numerous SNPs were 
associated with BUN levels (Table 6) in the comprehensive group; while no associations were 
found with dolutegravir. The top two SNPs in the comprehensive group rs4149117 and 
rs7311358 were found to be in LD (r2=1); the third (rs1799930) and fourth (rs1041983) SNPs 
were highly related (r2=0.882) as well; the four SNPs in SLC15A2 were also in high LD 
(rs1143671 vs rs2293616/rs2257212, r2=1; rs1143671 vs rs1143672, r2=0.978); and the 
VKORC1 gene SNPs as mentioned in the AST section earlier. Elvitegravir associations were 
found between BUN levels and six SNPs. Several SNPs were discovered to be significant in 
association with raltegravir-dosed subject BUN levels. The LD was similar to the elvitegravir 
group with rs2293616 vs rs1143671/rs2257212 yielding r2=1 and rs2293616 vs rs1143672 
showing r2=0.912; however, the UGT2B7 SNPs (rs7662029 and rs7668258) in this group were 
also in LD (r2=1). 
 
 
 
 
 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
ALL SLCO1B3 rs7311358 12 21015760 G 0.205 0.014 1.65 (0.43 — 2.86) 0.010 
 NAT2 rs1799930 8 18258103 A 0.335 0.192 -1.21 (-2.30 — -0.12) 0.033 
 NAT2 rs1041983 8 18257795 T 0.364 0.169 -1.16 (-2.23 — -0.10) 0.036 
 CYP2D6 rs1080985 22 42528382 G 0.216 0.337 2.00 (0.53 — 3.46) 0.009 
 VKORC1 rs7294 16 31102321 A 0.455 0.502 1.62 (0.41 — 2.84) 0.011 
 COMT rs4680 22 19951271 G 0.455 0.534 -1.51 (-2.64 — -0.37) 0.011 
 SLC15A2 rs2293616 3 121641693 C 0.483 0.966 1.29 (0.09 — 2.48) 0.039 
 SLC15A2 rs2257212 3 121643804 G 0.483 0.966 1.29 (0.09 — 2.48) 0.039 
 SLC15A2 rs1143671 3 121647286 C 0.483 0.966 1.29 (0.09 — 2.48) 0.039 
 SLC15A2 rs1143672 3 121648168 G 0.477 0.804 1.29 (0.09 — 2.48) 0.039 
 VKORC1 rs9934438 16 31104878 A 0.318 0.723 -1.27 (-2.48 — -0.06) 0.044 
 VKORC1 rs9923231 16 31107689 T 0.318 0.723 -1.27 (-2.48 — -0.06) 0.044 
 
Table 6: SNPs significantly associated with BUN levels 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for BUN levels 
adjusted for covariates [sex, age, BMI, integrase inhibitor, integrase inhibitor duration, and baseline BUN levels] 
 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
Elvitegravir CYP2D6 rs1080985 22 42528382 G 0.217 0.575 4.48 (1.58 — 7.38) 0.008 
 COMT rs4680 22 19951271 G 0.391 0.329 -3.35 (-5.23 — -1.47) 0.003 
 CYP2C9 rs28371685 10 94981224 T 0.022 1.000 8.84 (1.74 — 15.93) 0.027 
 COMT rs737865 22 19930121 C 0.196 0.329 -3.02 (-5.57 — -0.45) 0.035 
 VKORC1 rs7294 16 31102321 A 0.413 0.799 3.85 (0.47 — 7.23) 0.040 
 CYP2C8 rs1058930 10 96818119 G 0.043 1.000 -7.10 (-13.50 — -0.70) 0.045 
Raltegravir CYP1A1 rs1048943 15 75012985 G 0.022 1.000 10.52 (1.35 — 19.69) 0.044 
 SLC15A2 rs1143672 3 121648168 G 0.370 1.000 3.75 (0.54 — 6.95) 0.041 
 SLC15A2 rs2293616 3 121641693 C 0.391 1.000 3.75 (0.54 — 6.95) 0.041 
 SLC15A2 rs2257212 3 121643804 G 0.391 1.000 3.75 (0.54 — 6.95) 0.041 
 SLC15A2 rs1143671 3 121647286 C 0.391 1.000 3.75 (0.54 — 6.95) 0.041 
 UGT2B15 rs1902023 4 69418747 T 0.435 0.049 -3.82 (-6.64 — -0.99) 0.021 
 UGT2B7 rs7662029 4 69961912 A 0.413 0.799 3.42 (0.74 — 6.10) 0.028 
 UGT2B7 rs7668258 4 69962078 T 0.413 0.799 3.42 (0.74 — 6.10) 0.028 
 
Table 6: SNPs significantly associated with BUN levels (continued) 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for BUN 
levels adjusted for covariates [sex, age, BMI, integrase inhibitor, integrase inhibitor duration, and baseline BUN levels] 
 
 
 
All estimated glomerular filtration rates (eGFR) were under the normal range of greater 
than 90 mL/min/1.73 m2 (comprehensive group, 63.45±16.54 mL/min/1.73 m2; dolutegravir 
group, 61.88±15.97 mL/min/1.73 m2; elvitegravir group, 63.43±15.73 mL/min/1.73 m2; and 
raltegravir group, 66.41±18.67 mL/min/1.73 m2). Regimen differences in mean eGFR were not 
significant (p=0.590). Exploration of eGFR uncovered three SNPs (Table 7) that presented 
significant positive association across regimens (rs4986989, rs34130495, and rs3213619). 
Significance was not found concerning eGFR levels in dolutegravir dosing. In elvitegravir group 
analysis, five different SNPs were associated following multiple regression; however, 
rs28371686 and rs28399454 as well as rs4149117 and rs7311358 were in strong LD (r2=1). Each 
SNP, apart from rs717620, was associated with a decrease of eGFR with each minor allele. 
Evaluation of the raltegravir group identified no SNPs that were associated with eGFR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Gene SNP Chromosome BPa A1b MAFc HWEd Beta (95% CI)e p-value 
ALL NAT1 rs4986989 8 18222008 T 0.023 1.000 14.81 (2.65 — 26.97) 0.019 
 SLC22A1 rs34130495 6 160560824 A 0.017 1.000 13.01 (0.83 — 25.19) 0.039 
 ABCB1 rs3213619 7 87230193 C 0.028 1.000 10.20 (0.27 — 20.12) 0.048 
Elvitegravir CYP2C9 rs28371686 10 96741058 G 0.022 1.000 -20.67 (-36.33 — -5.01) 0.019 
 CYP2A6 rs28399454 19 41351267 A 0.022 1.000 -20.67 (-36.33 — -5.01) 0.019 
 SLCO1B3 rs4149117 12 21011480 T 0.283 0.069 -5.08 (-9.27 — -0.89) 0.029 
 SLCO1B3 rs7311358 12 21015760 G 0.283 0.069 -5.08 (-9.27 — -0.89) 0.029 
 ABCC2 rs717620 10 101542578 A 0.130 1.000 7.74 (0.83 — 14.64) 0.041 
 
Table 7: SNPs significantly associated with eGFR 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Beta for eGFR 
adjusted for covariates [integrase inhibitor (in All group), integrase inhibitor duration, and baseline eGFR] 
 
 
 
Discussion 
The purpose of this study was to examine the effects of genetics, adjusted for individual 
patient characteristics, on systemic INSTI exposure along with hepatic and renal tolerability. We 
found that in this population of primarily Caucasian male subjects that the majority were virally 
suppressed and tolerating their respective regimens (Table 1).   
The concentration of dolutegravir we found was below the geometric means previously 
reported as 1070 ng/mL and 1500 ng/mL for dolutegravir (19) and 
dolutegravir/abacavir/lamivudine (20), respectively. Based on reported geometric mean 
elvitegravir concentrations of 490 ng/mL, in the formulation containing tenofovir disoproxil 
fumarate (21), and 290 ng/mL, in the tenofovir alafenamide formulation (22), our mean 
concentration was somewhat less. Our average raltegravir Ctrough concentration of 567.16 ng/mL 
was much higher than the geometric mean 142 nM (approximately 68.52 ng/mL) previously 
reported (23). The reductions seen in our study may have several explanations ranging from 
subject reported dosing to differences in food intake (6, 24). 
 None of the SNP-associations that we found with dolutegravir have been reported 
elsewhere (Table 2). Additionally, none of these genes are known to interact with dolutegravir. 
Concerning ABCB1 SNP (rs1045642), an absence of correlation has been reported with 
dolutegravir plasma concentration (25) and this supports the absence of the association in seen in  
our study. The high variability within dolutegravir concentrations coupled with small sample size 
and distribution of genotypes necessitate confirmation, but the presence of associations may 
serve as a road map to future discovery. These SNP-associations would be very important to 
confirm as the effects are rather large (Table 2). 
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The absence of any associations in the elvitegravir and raltegravir groups may be a 
function of further reduced sample size through inability to detect drug concentrations. 
Alternatively, the reason could be a property of the selected SNPs. UGT1A1*28/*28 (AA in 
rs8175347) has been shown to yield higher raltegravir in blood (26); UGT1A1*28 has produced 
a mild reduction in elvitegravir clearance (27); and homozygous UGT1A1*28 has also been 
shown to increase dolutegravir exposure (28). This SNP; however, was not included on the 
panel. Also some of the included SNPs, 1128503, rs2032582, rs1045642, and rs2231142, have 
previously been found to not change raltegravir Ctrough, but they did find alterations in peak 
concentrations (25). We would not have seen this effect as we only took Ctrough. 
In this study, no regimen grouping of subjects showed a mean ALP level outside the 
normal range which suggests that these associations may not be clinically significant unless other 
factors are involved. In a previous study by Tebas et al., dolutegravir, when co-administered with 
abacavir and lamivudine, was shown to increase bone-specific alkaline phosphatase by a 50% 
change from baseline following 144 weeks of administration (29). Additionally, when switching 
from an efavirenz-based regimen to a raltegravir-based regimen, serum ALP was significantly 
decreased in the raltegravir group compared to an efavirenz group at 24 weeks (30). In our study, 
the alkaline phosphatase was nonspecific; however, an increase in the bone-specific form would 
elevate the nonspecific form. It seems that none of the SNPs, which showed significance in this 
study, have been previously reported to influence ALP levels (Table 3). Although many showed 
high variability, most, apart from rs7294, found that adding a minor allele would tend to increase 
ALP levels. The genes identified with ALP levels in this study include transporters (ABCC2) 
and metabolizing enzymes (CYP2C8) (31). Thus, these changes may occur through drug 
remaining in hepatocytes rather than being pumped out. 
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ALT levels were not significantly altered among treatment groups. None of the ALT-
SNP associations (Table 4) we presented have been previously reported to the best of our 
knowledge. A study conducted in a Japanese population did find that female subjects with 
homozygous A alleles in rs4680 had lower odds ratios, when using logistic regression, of having 
elevated ALT levels compared to both homozygous G alleles and heterozygous individuals with 
a similar trend was found in males aged 45-54 (32). We did not see an association with rs4680 in 
any of our groups for ALT levels. In our study, the transporter SLC22A1 appeared frequently 
which may indicate, as noted earlier with ALP, that drug accumulation may play a role in these 
associations. 
Although none of the mean AST levels were above normal, the elvitegravir group had a 
very high variation. This variation may have inflated the betas for the multiple linear regression 
results at least for the comprehensive and the elvitegravir groups. Otherwise none of the 
presented SNPs (Table 5) have been reported elsewhere in relation to AST levels. As suggested 
with ALP and ALT, drug accumulation or lack thereof may explain the minor alterations in 
hepatic function enzymes. Overall, these regimens appear to be relatively well tolerated in terms 
of hepatic outcomes. However, some of the polymorphisms may have a large effect on respective 
marker levels. Thus, these may need to be monitored closely in certain patients.  
 In regard to renal effects, many SNP associations were found with BUN levels (Table 6); 
however, most effects were minor. There were a large number of SNPs in LD within these 
groupings which lowers the number of useful polymorphisms; however, these SNPs have not 
been previously identified as relating to BUN. Even if these SNPs associations are confirmed, 
the likelihood of clinical significance is small unless other problem factors are present. 
43 
 
Mean eGFR was lower than normal across all groups; however, this is common in those 
receiving antiretrovirals. While eGFR did not seem to be related to dolutegravir or raltegravir 
alone, the three SNPs in the comprehensive group seemed to improve renal function (Table 7). 
Meanwhile, the associated SNPs found in elvitegravir each lowered eGFR. These may need to be 
examined more closely to protect against renal insufficiency. As all of the elvitegravir groups 
contained a form of tenofovir, especially tenofovir disoproxil fumarate, as well as cobicistat, 
these lower values may be a function of renal damage or creatinine clearance changes (7, 33). In 
addition, alterations in the movement of drugs in renal tubular cells may have contributed to the 
associations identified.    
The strong LD of certain SNPs in this population would allow for the use of one SNP to 
cover the presence of both if r2 equals 1, which may be useful in the reduction of redundant 
genotyping. In future studies which seek to analyze these exploratory associations, SNPs which 
show LD may need to undergo haplotype analysis to further understand associations.  
This study had a few limitations. The first being the low sample size, in terms of regimen 
group size and the occurrence of different alleles, which may have influenced study outcomes. 
Another limitation is the relatively homogenous population, predominately Caucasians which 
may prevent analysis of SNPs that occur more frequently in different races; however, population 
specific SNPs may be examined in greater numbers. 
In conclusion, we determined that several SNPs found on the iPLEX panel were 
significantly associated with various patient outcomes. The large number of previously 
unreported associations may be due to the absence of clinical significance which may have 
precluded publication. More studies are needed, preferably in a larger population to determine 
the clinical applicability of our findings.  
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Methods 
Subject recruitment  
All personnel, involved in patient contact and/or private health information use, received 
the necessary training through the Collaborative Institutional Training Initiative program and 
various other programs for ETSU/Veterans Affairs (VA) Medical Campus Institutional Review 
Board (IRB) approval. Recruitment for this observational study was conducted between July 
2015 and February 2017. Those individuals, being HIV-1 positive, who met the inclusion criteria 
(≥18 years old, non-pregnant, and receiving an INSTI regimen) were contacted by phone. 
Interested subjects were advised of a requisite regimen dosing schedule which would allow for 
the capture of the Ctrough required for this study without influencing antiretroviral efficacy. 
Informed consent was obtained in the presence of at least one investigator and witness. A review 
of subject electronic health records was also performed. Subjects were compensated with a gift 
card, with documentation of receipt, at the completion of study participation. 
Dolutegravir regimens consisted of the single tablet regimen of dolutegravir (50 
mg)/abacavir (600 mg)/lamivudine (300 mg), dolutegravir (50 mg) plus tenofovir disoproxil 
fumarate (300 mg)/emtricitabine (200 mg), or dolutegravir (50 mg) plus tenofovir alafenamide 
(25 mg)/emtricitabine (200 mg). Subjects on an elvitegravir regimen received one of two once-a-
day forms [elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir disoproxil fumarate (300 
mg)/emtricitabine (200 mg) or elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir alafenamide 
(10 mg)/emtricitabine (200 mg)]. Raltegravir was given twice-a-day concurrently with once-a-
day tenofovir disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25 
mg)/emtricitabine (200 mg). A form of the tenofovir/emtricitabine background was used in over 
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67% over subjects. Other antiretrovirals, such as protease inhibitors, were included in some 
patients. Background regimens were not included in analysis. 
Clinical Tolerability Analysis 
Baseline values for hepatic and renal parameters were taken at the closest available point 
prior to starting the regimen of interest; while current parameters were taken from the closest 
possible point relative to sample collection. Sample collection and previous dosing times were 
recorded in the questionnaire. Estimated glomerular filtration rate (eGFR) was calculated using 
the 2009 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) based upon plasma 
creatinine. Comparison between regimens was conducted using one-way ANOVA with SPSS 25. 
Drug Exposure Analysis 
The Ctrough measurement has been used in previous studies with success and is less 
invasive than traditional inpatient pharmacokinetic sampling (34, 35). Trained phlebotomists 
collected whole blood sample (20 mL) at the end of respective regimen dosing intervals (24 
hours for dolutegravir and elvitegravir as opposed to 12 hours for raltegravir). Plasma, for 
pharmacokinetic analysis, and remaining cells, for genetic testing, were separated then placed at 
-80 °C until analysis.  
Samples were analyzed using an LC-MS method developed by Simiele et al. with 
modifications (36). Briefly, a standard curve ranging from 10 ng/mL to 1,500 ng/mL was created 
for drugs of interest from respective stock solutions in a 50:50 ratio of acetonitrile and water, 
using blank human plasma (Innovative Research Inc Novi, MI). Verapamil, a drug which no 
subject was concurrently receiving, was used as the internal standard in acetonitrile and 1% 
formic acid in water (80:20). Pharmacokinetic samples (1 mL) underwent pH viral inactivation 
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over a period of 1 hr at ambient temperature (23 °C) at a pH of 4, achieved using the addition of 
100 µL of 1M HCL (37). One hundred microliters of internal standard were added then samples 
were vortex mixed. Sample (200 µL) and 0.1% formic acid in acetonitrile (600 µL) were 
aspirated in Ostro pass-through sample preparation 96-well plates (Waters Corporation, Milford, 
MA). Collected samples underwent direct chromatography with a Waters X-Select HSS T3 
column (150 x 4.6 mm, 3.5 micron) and a gradient of 0.1% formic acid in water (A) and 0.1% 
formic acid in acetonitrile (B) (5-100 %). Mass spectrometric detection was achieved using 
direct MS/MS channels for each drug, specific to their [M+H]+ ion. All solvents used for LC-
MS/MS analysis were of LC-MS Grade from Honeywell-Burdick and Jackson (Muskegon, MI). 
Stock chemicals were purchased from Chemscene (Monmouth Junction, NJ).  
Pharmacogenetic Analysis 
A Sequenom iPLEX® ADME PGx Panel v1.0 (Sequenom, San Diego, CA) comprised of 
assays for numerous genetic areas of interest, was used to evaluate the genetic profile of each 
subject. DNA extraction and genotyping were performed at the Vanderbilt Technologies for 
Advanced  Genomics (VANTAGE) according to manufacturer specifications. Briefly, following 
extraction from whole blood (Autopure LS, QIAGEN, Hilden, Germany), DNA was amplified 
via PCR then free nucleotides were dephosphorylated. The iPLEX Gold reaction, being the 
addition of a primer to the site of interest which is then extended by one nucleotide based on 
genotype, was conducted. A MassARRAY® Analyzer returned subject alleles and the 
MassARRAY Typer was used to determine genotype call rates. Hardy-Weinberg equilibrium 
(HWE), minor allele frequency (MAF), and pairwise linkage disequilibrium (LD) statistics (r2) 
were assessed using HAPLOVIEW software (38).  
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SNPs are represented with the more frequent allele in the specific sampling being 
identified as the reference; while the less frequent allele was identified as the minor allele 
(reference allele>minor allele). Subject genotypes were analyzed using the additive genetic 
association model. As such the dosage of minor allele was considered to have an additive effect 
for example homogenous major alleles were coded as 1, heterogenous alleles as 2, and 
homogenous minor alleles as 3. Then, to test for association with quantitative traits, multiple 
linear regression, with the inclusion of covariates [age, sex, BMI, regimen (in the across regimen 
group), regimen duration, and baseline variables (as required)], were performed by PLINK v1.07 
to obtain the regression coefficient and p-value (39). Correction for multiple testing was not 
conducted due to the exploratory nature of this study (40). Subject information, following de-
identification, was uploaded into the ETSU version of REDCap (41). 
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Study Highlights 
o  What is the current knowledge on the topic?  
Pharmacogenetics play an important role in selected outcomes of drug dosing.   
o What question did this study address?  
This study sought to explore the relationship of selected single nucleotide polymorphisms 
(SNPs) with drug exposure as well as respective patient hepatic and renal effects in subjects 
receiving HIV integrase strand transfer inhibitors (INSTIs).   
o What does this study add to our knowledge?  
Several SNPs were identified that had previously been unrelated to clinical variables in INSTIs. 
This exploratory study seeks to slightly expand the frame through which researchers are looking 
to promote new lines of inquiry. 
o How might this change clinical pharmacology or translational science? 
The associations found in this study may spark interest in otherwise uncritically explored 
genomic areas. If these results are supported and expanded in larger trials, new suggestions 
and/or precautions for INSTI dosing may be developed. 
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Abstract 
Dolutegravir, elvitegravir, and raltegravir, are widely utilized HIV integrase strand transfer 
inhibitors (INSTIs). As side effect occurrence varies among patients receiving these drugs, we 
investigated the role of several single nucleotide polymorphisms (SNPs) in subject-reported 
adverse events. SNPs underwent multiple logistic regression for association (p<0.05) with binary 
traits including central nervous system-related (abnormal dream, anxiety, fatigue, headache, and 
insomnia) and gastrointestinal-related (diarrhea and nausea) adverse events adjusted for age, sex, 
BMI, and regimen duration along with specific regimen in the comprehensive group (included all 
patients). HIV+ adults (≥18 years old) receiving an INSTI were recruited (n=88). Abnormal 
dream occurrence was found to be associated (p=0.028) with regimen-received. Additionally, 
several SNPs were found to be associated with adverse event profiles primarily in the 
comprehensive group. In conclusion, the associations found in this study strengthen the need for 
further assessment, within the HIV positive population, of factors contributing to unfavorable 
patient outcomes. 
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Introduction 
After nearly four decades, the human immunodeficiency virus (HIV) remains a high 
priority in scientific research with thousands of new infections occurring each day adding to the 
upward of 36 million HIV positive individuals worldwide (1). Current antiretroviral therapy is 
highly effective in reducing plasma HIV viral load; however, several factors may impact the 
efficacy and tolerability of antiretrovirals (2-4). Of the four currently available integrase strand 
transfer inhibitors (INSTIs), clinical experience is greatest with dolutegravir, elvitegravir, and 
raltegravir (5). Nausea and headache are the most frequent adverse events associated with 
dolutegravir (6) with neuropsychiatric adverse events in general having been reported as reasons 
for changing regimens (7). Meanwhile, elvitegravir and raltegravir also show central nervous 
system (CNS) as well as gastrointestinal (GI) adverse events (8-10).  
While many factors contribute to the patient outcomes, variations in the genetic make-up 
of an individual may also alter the behavior of some drugs resulting in differences in both 
efficacy and toxicity (11). For example, reduction in the activity and/or expression of metabolic 
enzymes or transporters may greatly influence drug pharmacokinetics and thereby alter patient 
outcomes (12-14). As adverse effect profiles often play an important role in the selection and 
maintenance of antiretroviral therapy, we sought to identify associations between the occurrence 
of  CNS and GI adverse events with single nucleotide polymorphisms (SNPs) in an exploratory 
cohort of patients receiving currently available INSTIs. 
Results 
Eighty-eight HIV positive adults (comprehensive group), differentiated by INSTI 
(regardless of nucleoside backbone), dolutegravir group (n=42, 88.1% male), elvitegravir group 
(n=23, 87.0% male), or raltegravir group (n=23, 82.6% male) were recruited. Further 
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demographic information has been previously reported by our group (15). Adverse event 
occurrence stratified by genotype, in significant associations, are shown in supplemental tables. 
Central Nervous System Adverse Events 
Abnormal Dream Occurrence. With a significant association (p=0.028) between regimen 
and adverse event occurrence, abnormal dreams were reported more frequently in the raltegravir 
group (30.4%) compared with either the elvitegravir (4.3%) or the dolutegravir group (9.5%). 
One SNP (rs1143672) was determined to have a protective (decreased occurrence likelihood) 
association with abnormal dreams in the comprehensive group (Table 1). Dolutegravir and 
elvitegravir stratification yielded no significant SNPs; while one SNP (rs1128503) was 
associated with decreased abnormal dream occurrence in the raltegravir group when minor 
alleles were present.   
 
 
CNS  
adverse event Drug Gene SNP Chromosome BP
a A1b MAFc HWEd OR (95% CI)e p-value 
Abnormal  
Dreams ALL SLC15A2 rs1143672 3 121648168 G 0.477 0.804 0.31 (0.11 — 0.93) 0.037 
 Raltegravir ABCB1 rs1128503 7 87179601 T 0.370 0.644 0.07 (0.01 — 0.98) 0.049 
Anxiety ALL SLC15A2 rs1143672 3 121648168 G 0.477 0.804 0.45 (0.22 — 0.92) 0.028 
  VKORC1 rs9934438 16 31104878 A 0.318 0.723 2.08 (1.01 — 4.30) 0.048 
  VKORC1 rs9923231 16 31107689 T 0.318 0.723 2.08 (1.01 — 4.30) 0.048 
Fatigue ALL ABCB1 rs1128503 7 87179601 T 0.358 0.764 0.33 (0.15 — 0.76) 0.009 
  CYP2E1 rs2070673 10 135340567 A 0.210 1.000 2.62 (1.14 — 6.01) 0.023 
  UGT2B15 rs1902023 4 69418747 T 0.494 0.181 2.08 (1.10 — 3.93) 0.025 
 Raltegravir CYP2D6 rs3892097 22 42524947 A 0.152 1.000 20.59 (1.51 — 280.40) 0.023 
  CYP2D6 rs1065852 22 42526694 T 0.174 1.000 16.40 (1.21 — 222.90) 0.036 
  SLC22A2 rs316019 6 160670282 T 0.109 1.000 17.83 (1.07 — 297.10) 0.045 
 
Table 1: SNPs significantly associated with CNS adverse event occurrence  
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Odds ratio for 
CNS adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor 
duration] 
 
 
CNS  
adverse event Drug Gene SNP Chromosome BP
a A1b MAFc HWEd OR (95% CI)e p-value 
Headache ALL GSTP1 rs1695 11 67352689 G 0.347 1.000 3.53 (1.46 — 8.55) 0.005 
  SLCO1B1 rs2306283 12 21329738 G 0.477 0.499 0.42 (0.19 — 0.92) 0.031 
  ABCB1 rs3213619 7 87230193 C 0.028 1.000 18.37 (1.86 — 181.90) 0.013 
Insomnia ALL VKORC1 rs9934438 16 31104878 A 0.318 0.723 2.70 (1.14 — 6.38) 0.024 
  VKORC1 rs9923231 16 31107689 T 0.318 0.723 2.70 (1.14 — 6.38) 0.024 
 
Table 1: SNPs significantly associated with CNS adverse event occurrence (continued) 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Odds ratio for 
CNS adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor 
duration] 
 
 
Anxiety Occurrence. Anxiety was reported in 29.5% of the comprehensive grouping; 
while dolutegravir, elvitegravir and raltegravir groups presented with 33.3%, 17.4%, and 34.8%, 
respectively. No significant interaction was found between regimen and anxiety occurrence 
(p=0.368). In the comprehensive group, three SNPs, one protective (rs1143672) and two 
increasing occurrences (rs9934438 and rs9923231), showed association with increased anxiety 
occurrence (Table 1). Additionally, rs99234438 was in LD (r2=1.00) with rs9923231. When 
regimens were tested as individual groups, there were no significantly associated SNPs.  
Fatigue Occurrence. The occurrence of fatigue was frequent in each of the groups 
(comprehensive; 33.0%; dolutegravir; 33.3%; elvitegravir, 30.4%; and raltegravir; 34.8%). As 
such, no association was found between fatigue and regimen (p=1.000). Three SNPs, rs1128503 
(decreased occurrence), rs2070673 (increased occurrence) , and rs1902023 (increased 
occurrence), were associated with fatigue (Table 1) in the comprehensive group. Concerning the 
dolutegravir and elvitegravir patients, fatigue occurrence was not associated with any SNPs 
following multiple logistic regression. Raltegravir regimen grouping revealed three SNP 
associations (rs3892097, rs1065852, and rs316019) with increased fatigue occurrence. 
Headache Occurrence. Headaches occurred most frequently in the dolutegravir group 
(33.3%) followed by the raltegravir group (17.4%) then the elvitegravir group (8.7%) with 
overall occurrence being 22.7% of all patients. No association (p=0.066) was determined 
between regimen and occurrence. While no logistic associations were found among the 
individual regimens, three SNP-headache occurrence associations (Table 1) were discovered in 
the comprehensive group. These ranged to from decreasing occurrence (rs3213619) to slight 
elevation (rs1695) to larger increased frequency of occurrence (rs3213619).   
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Insomnia Occurrence. Insomnia was reported in 19.3% of patients overall which was 
matched well with the 19.0% seen in dolutegravir. Meanwhile, elvitegravir and raltegravir 
demonstrated differing rates with 8.7% and 30.4%, respectively. No association (p=0.190) was 
determined to exist through Fisher’s exact testing. As shown in Table 1, one gene contained 
SNPs (rs9934438 and rs9923231) which, when analyzed across regimens in the comprehensive 
group, were significantly associated with increased insomnia occurrence. As noted earlier the 
SNPs, rs9934438 and rs9923231, were in LD (r2=1.00). Individual drug groups showed no 
associations. 
Gastrointestinal adverse events 
Diarrhea Occurrence. With an overall occurrence in 29.5% of patients, dolutegravir, 
elvitegravir, and raltegravir grouping yielded 30.9%, 26.1%, and 30.4%, respectively. As the 
presence of diarrhea was rather evenly distributed among groups, no association (p=0.955) 
between this adverse event and regimen was found. One SNP (rs4680) exhibited a protective 
association in the comprehensive group (Table 2); meanwhile, no other diarrhea-SNP 
associations were found.  
 
 
 
 
 
 
GI Adverse 
Event Drug Gene SNP Chromosome BP
a A1b MAFc HWEd OR (95% CI)e 
 
p-value 
Diarrhea ALL COMT rs4680 22 19951271 G 0.455 0.534 0.42 (0.19 — 0.91)  0.027 
Nausea ALL GSTP1 rs1695 11 67352689 G 0.347 1.000 2.82 (1.09 — 7.29)  0.033 
  NAT2 rs1208 8 18258316 G 0.398 0.447 2.64 (1.07 — 6.50)  0.034 
 
Table 2: SNPs significantly associated with GI adverse event occurrence 
 
a
Physical position (bp); 
b
Minor allele; 
c
Minor Allele Frequency; 
d
p-value for Hardy-Weinberg equilibrium test; 
e
Odds ratio for GI 
adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor 
duration] 
 
 
Nausea Occurrence. Nearly one in five of all patients (18.2%) experienced nausea. 
Dolutegravir grouping exhibited   slightly higher occurrence at 23.8%; while elvitegravir and 
raltegravir both showed an occurrence of 13.0%. No significance (p=0.459) was found between 
regimen and nausea occurrence. In the cumulative regimen group, two SNPs, rs1695 and rs1208 
(Table 3), were associated with increased nausea occurrence; however, individual drug grouping 
eliminated associations.  
Discussion 
The purpose of this study was to examine the effects of individual characteristics on adverse 
event occurrence in the use of INSTI regimen. Successful completion of this project sought to 
identify methods for predicting and possibly preventing negative outcomes.  
Central Nervous System Adverse Events 
Abnormal Dream Occurrence. When dolutegravir (50 mg) was dosed once daily to 
healthy patients over five days, 8% (1/12) of patients experienced abnormal dreams (16). This 
report is similar to the finding in our cohort at 9.5%. The occurrence of abnormal dreams in 
elvitegravir found in our study (4.3%) was lower than those previously reported by Wohl et al.. 
That study reported 15% and 16% occurrence in a sample size of 348 patients following 96 and 
144 weeks, respectively, when elvitegravir in combination with cobicistat, emtricitabine, and 
tenofovir disoproxil fumarate was dosed (8). More patients may have had a higher frequency of 
alternate genotypes than those observed in our study. In the STARTMRK and BENCHMRK 
trials under all causalities, 7.5% and 0.9% experienced abnormal dreams when taking raltegravir 
(17). This was much lower than our 30.4%.  
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The SNP, rs1143672, appears to have not been previously associated with abnormal 
dreams. The ABCB1 SNPs which were associated with abnormal dream occurrence in the 
raltegravir group may be related to an alteration of raltegravir concentrations in cerebrospinal 
fluid (18). A higher, although nonsignificant (p=0.4419), trough concentration of raltegravir has 
been reported in patients with genotypes differing from the homozygous G alleles (255±161 
ng/mL vs 441±525 ng/mL) (19). In that study, rs1128503 did not influence raltegravir trough 
concentration nearly as much (480±348 ng/mL vs 404±505 ng/mL; p=0.8019). The protective 
effects seen in our study should be studied further to determine the interaction.  
Anxiety Occurrence. In a 96 weeks study of dolutegravir plus a nucleoside reverse 
transcriptase inhibitor backbone, 5% of patients presented with anxiety (20); while in a study 
using dolutegravir/abacavir/lamivudine,  anxiety has been reported in 2% of patients (21). The 
difference seen in our study (33.3%) could be the duration of the specific regimens or the 
influence of concurrent medications drugs. The percentage of patients presenting with anxiety 
occurrence in our study (17.4%) was higher than those reported previously with 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate dosing 6% (94) and 10% (23). 
This could be the inclusion of other medications which were not considered in this study. In the 
SAILING study concerning raltegravir, 2% experienced anxiety; while 6% was discovered in the 
SPRING-2 ART cohort (24). The occurrence (34.8%) was much higher in our raltegravir 
grouping. 
Our results indicate that, overall, anxiety occurred across the tested INSTIs. The 
protective effect of rs1143672, in the SLC15A2 gene, with both abnormal dreams and anxiety 
may indicate changes in drug transport are contributing to these adverse events. VKORC1 SNPs 
occur frequently across variables; however, the mechanism of interaction, if valid, is unknown. 
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Fatigue Occurrence. The percentage of patients experiencing fatigue while taking 
dolutegravir in our study was 33.3%; while fatigue occurred in 6% and 4% of dolutegravir 
patients in two previous studies by Molina et al. (20) and Cahn et al. (9), respectively. In 
previous clinical studies concerning elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 
fumarate, fatigue was reported in 13% and 15% of patients at 96 weeks and 144 weeks, 
respectively (8). Even in the elvitegravir group, our findings of fatigue were twice (30.4%) those 
in the previous study. Fatigue was reported in 7% of raltegravir patients in one study (9) and 
3.9% of the patients from the STARTMRK study (17); while our values were more than five 
times higher at 34.8%. One explanation of the high values in our study is that we relied on 
patient reported occurrence without expansive clinical examination. Thus, the fatigue may have 
alternate causes. Regardless of mechanism, we found no association between regimen and 
fatigue occurrence in this population.  
The SNPs associated with fatigue in the comprehensive group showed relatively low 
variation as opposed to those in the raltegravir group. The results of this study seem to indicate 
that a few SNPs can strongly predict fatigue occurrence with raltegravir; however, the extent of 
the 95% confidence intervals are quite high. Upon confirmation in a larger population, the 
variation will likely be reduced as more individuals with differing genotypes may be present.  
Headache Occurrence. Seventeen percent of patients reported headaches when dosed 
with dolutegravir (20) compared with 9% in another study (9); while 3% experienced headaches 
when given dolutegravir/abacavir/lamivudine (21). All values were much lower than that 
observed in our study (33.3%). Our 8.7% occurrence of headaches within the elvitegravir group 
was much lower than the 16% (at 96 weeks) and 18% (at 144 weeks) occurrence when given the 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate regimen (8). Headache 
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occurrence was reported in 9% of raltegravir patients in one study (9); while the STARTMRK 
study yielded 9.3% (20). Both lower than our 17.4%. Although different, no significant 
association between regimen and outcome was not found which matches our results of no 
association within individual groups. The strong positive association seen with rs3213619, which 
likely occurs due to alteration in drug transport, had high variability; however, upon 
confirmation, this SNP may be clinically important for those wishing to avoid headaches.  
Insomnia Occurrence.  Molina and colleagues reported insomnia in 8% of patients 
receiving dolutegravir (20); meanwhile, Walmsley et al. showed 4% occurrence when using 
dolutegravir/abacavir/lamivudine (21). This is less than half of the percentage found in our study 
(19.0%). Our insomnia occurrence (8.7%) was somewhat less than the 11% and 12% reported 
for elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate at 96 and 144 weeks (8). 
Also, the four percent of patients experienced moderate-to-severe insomnia in a previous study 
concerning raltegravir (25) was much lower than our 30.4%. This may have been because we 
included any occurrence of insomnia rather than moderate to severe. The high variability across 
regimens would explain the absence of significant association between regimen and insomnia. 
Once again VKORC1 shows association, but the interaction is unknown. 
Gastrointestinal Adverse Events 
Diarrhea Occurrence. Nearly one third of our patients (30.9%) reported diarrhea in the 
dolutegravir group. Previously 18% of dolutegravir receiving patients reported diarrhea in the 
study by Molina et al. (20) and 20% in the study by Cahn and colleagues (9); meanwhile 5% was 
reported when dolutegravir/abacavir/lamivudine was given (21). We found nearly identical 
occurrence (26.1%) of diarrhea as those reported for 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (25% and 26%) at 96 and 144 
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weeks (8). Diarrhea was reported in 18% of raltegravir patients (9); while the STARTMRK 
study reported 5.0% (20). The values are much smaller than our 30.4%. The distribution of 
diarrhea in our patients was relatively uniform; thus, explaining the lack of association between 
regimen and diarrhea. As catechol-o-methyltransferase, which had a significant SNP in the 
comprehensive analysis, is involved in neurotransmitter metabolism the mechanism of 
interaction with diarrhea not evident; however, the effect is not large (26).    
Nausea Occurrence. Nausea was reported in 17% of patients receiving dolutegravir alone 
(20); 8% in another study (9); and 2% in a dolutegravir/abacavir/lamivudine study (21). While in 
our study 23.8% of patients reported nausea, this was similar to the first study, but much larger 
than the latter two. Previously, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate 
showed 22% (96 weeks) and 23% (144 weeks) occurrence of nausea (8). These values are 
actually a bit larger than our 13%. Nausea has been previously reported in 8% of raltegravir 
patients (9) and 8.5% in the STARTMRK results (20). Once again, our value is a bit higher at 
13%. As the values reported in our study are relatively close across regimens, no association was 
found in Fisher’s exact testing. The associated SNPs in the comprehensive group both increase 
the likelihood of nausea, but the mechanism unclear. 
In addition to the limitations previously reported (15), such as small sample size, this 
study depended on patient-reported adverse event occurrence which may be limited by patient 
recall. These events were also left to the determination of the patient rather than clinical workup. 
Also, we may have missed important SNPs as this was not a genome wide association study. 
These results indicate that pharmacogenetics may play an important role in predicting the 
adverse effect profile of integrase inhibitor-based regimens. As the identification of patient 
outcome determinants contributes to better utilization of medication, especially in first line 
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therapies such as INSTIs, these exploratory findings provide support for further examination of 
precision medicine in HIV pharmacotherapy. In conclusion, the associations found in this study 
strengthen the need for further assessment within the HIV positive population of factors 
contributing to unfavorable patient outcomes.  
Methods 
Subject Recruitment  
This study, as previously reported (15), was approved by the East Tennessee State 
University (ETSU)/VA Medical Campus Institutional Review Board (IRB). Patients were 
recruited as delineated in Figure 1. Briefly, non-pregnant adults (≥18 years) on an INSTI 
regimen for HIV-1 were eligible. Following the receipt of informed consent, side effect 
occurrence, including central nervous system-related (abnormal dream, anxiety, fatigue, 
headache, and insomnia) and gastrointestinal-related (diarrhea and nausea), was treated as a 
binary outcome (occurrence vs nonoccurrence) regardless of frequency was assessed with a 
questionnaire.   
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Dolutegravir grouping included patients receiving 50 mg of dolutegravir in combination 
with abacavir (600 mg)/lamivudine (300 mg) in a single tablet or dosed with either tenofovir 
disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25 
mg)/emtricitabine (200 mg). The elvitegravir grouped patients were administered either 
elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir disoproxil fumarate (300 mg)/emtricitabine 
(200 mg) or elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir alafenamide (10 
mg)/emtricitabine (200 mg) once daily. Raltegravir (400 mg) taken every 12 hours along with 
tenofovir disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25 
mg)/emtricitabine (200 mg) every 24 hours. Some patients were also receiving protease 
inhibitors in addition to the INSTI and background regimens. 
Figure 1: Subject Recruitment Schematic 
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Pharmacogenetic Analysis 
An iPLEX® ADME PGx Panel v1.0 (Sequenom, San Diego, CA) was utilized to 
interrogate patient SNPs. HAPLOVIEW software was used to determine Hardy-Weinberg 
equilibrium (HWE), minor allele frequency (MAF), and pairwise linkage disequilibrium (LD) 
statistics (r2) (27). The additive genetic association model was employed in this study with the 
most frequent allele being considered as a reference.  
Statistical Analysis 
De-identified patient information was stored in the ETSU version of REDCap (Research 
Electronic Data Capture), a secure web-based application (28). Fisher’s exact tests were used to 
evaluate independence of binary adverse event outcomes among regimens and genotypes using 
SPSS v25 (29). Clinical outcome associations with genotype were analyzed using multiple 
logistic regression with inclusion of covariates [age, BMI, sex, regimen duration, and specific 
regimen (in the comprehensive group)] via PLINK v1.07 (30). A p-value of greater than 0.05 
was set as the statistical cutoff. Correction for multiple testing across Fisher’s exact tests and 
logistic regression was not conducted due to the exploratory nature of this study (31). 
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Study Highlights 
o What is the current knowledge on the topic?  
HIV antiretrovirals, which successfully suppress viral load, require life-long dosing. As such, the 
occurrence of adverse events and the avoidance thereof have risen in importance. The first three 
available integrase strand transfer inhibitors (INSTI) have each displayed, although relatively 
rare, discontinuation-worthy adverse events.  
o What question did this study address?  
This study sought to analyze genetic influence, through single nucleotide polymorphism (SNP) 
association, on the occurrence of such adverse events in INSTI dosing. 
o What does this study add to our knowledge?  
Abnormal dreams may be related to raltegravir. Additionally, several SNP associations were 
discovered with various central nervous system gastrointestinal adverse events. These results 
may point to additional considerations in regimen selection. 
o How might this change clinical pharmacology or translational science? 
These associations, if confirmed in larger studies, may help practitioners to tailor patient 
regimens with greater accuracy. 
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CHAPTER 4 
CONCLUSIONS 
The purpose of this study was to test our hypothesis that particular drug outcomes would 
be influenced by the pharmacogenetics of an individual. In order to complete this project, we 
evaluated INSTI drug exposure in HIV-1 patients, documented genetic polymorphisms, collected 
clinical outcomes, and performed association analyses.  
Drug Exposure 
As outlined in Chapter 2, subjects in our study underwent Ctrough sample collection to fulfill 
specific aim one. Although this method of drug exposure determination was undoubtedly less 
complicated than comprehensive pharmacokinetic sampling, subjects, especially those on strict 
dosing schedules, were typically reluctant to alter their routine. Thus, many potential participants 
were disqualified. As Ctrough sample concentrations are characteristically low, analysis also 
proved to be a difficulty. Also, high variability was seen; however, this was expected in this drug 
class (Rizk et al., 2012). Additionally, differences in food intake (amount, time relative to 
dosing, and composition) may have also contributed to the variability (Lampiris, 2012; Olin et 
al., 2012). 
Owing to the lack of intra- and inter-day data as well as the few samples that yielded 
concentrations within respective standard curves (dolutegravir; n=23; elvitegravir, n=15; and 
raltegravir, n=6), these data were only tested against genotype. While associations were found 
only with dolutegravir, this may be a function of the others having much less variation within 
genotype in the already small sample size. However, as stated earlier, the associations (Table 
1.2) have not been reported prior to this study which may point to a new route of investigation. 
As with the other results of this study future confirmation will give a more definitive answer. 
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Genetic Analysis 
The second specific aim was conducted as delineated in Chapter 2. Although alternative, 
less invasive methods of DNA collection are available, the sampling used in this study was 
concurrent with the whole blood collection for Ctrough determination. The completion of this 
second aim was successful; however, in future studies the use of genome wide association 
studies (GWASs) may be more beneficial as one-to-one SNP to outcome relationships are rare. 
As opposed to individual SNP studies, several SNP studies (such as the present project), and 
whole exome studies (which analyze variation within segments of the genome which code for 
protein), a GWAS allows for more a comprehensive look into variations which may contribute to 
several outcomes. Expression analysis would also be very helpful as the amount of protein, in 
most cases, has a proportionate influence on activity (Elens et al., 2013; Okubo et al., 2013; 
Wang et al., 2011). Additionally, SNPs may not give the complete picture. A SNP alone, for 
example, may show full functionality regarding genotype; however, a regulating sequence may 
be inoperative.  
Clinical Outcomes 
The third aim of this project was carried out via two routes: electronic medical record 
review and questionnaire administration. Firstly, we decided to gather the results of patient 
metabolic panels as these were conducted routinely. The hepatic function outcomes (ALP, ALT, 
and AST) along with renal outcomes (BUN and eGFR) were gathered successfully (as outlined 
in Chapter 2). A majority of these values were found to reside within the normal ranges apart 
from ALT. These results likely indicate that INSTI do not generally have a large influence on 
hepatic and renal parameters which is helpful as other concurrent drugs may. The elevation in 
ALT may have been elicited through concurrent disease states or conditions. Overall, toleration 
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was high in terms of hepatic and renal outcomes. Secondly, a questionnaire was administered, as 
explained in Chapter 3. Included in the questionnaire, apart from typically demographic 
information, was the question of which adverse events occurred over the previous two weeks. In 
these outcomes, only abnormal dream occurrence was significantly related to regimen in which 
case raltegravir showed a higher occurrence.  
 In addition to the hepatic and renal information for the collection time and baseline 
values, consideration of more information regarding co-administered drugs may increase the 
accuracy of prediction. For example, subject outcomes may be dependent based on the duration 
of various background regimens. This suggestion would be more practical in a multiple 
personnel setting which would allow for evaluation of various aspects of data collection. Another 
improvement would be to have adverse events evaluated for relatedness to drug administration 
by a physician rather than relying on subject reported events. Subjects may, for example, suffer 
from migraine headaches or have an underlying psychological disorder which manifests in 
anxiety or insomnia. Thus, the occurrence of an adverse event may have been reported, but due 
to a preexisting condition or other factor rather than the drug of interest.      
Association Analyses 
Finally, association analyses were conducted, in completion of specific aim 4, between 
genotype information and the variables collected from pharmacokinetic and clinical outcomes 
observation. First, in terms of hepatic outcomes we saw numerous associations between 
genotype and ALP, ALT, and AST (Tables 1.3, 1.4, and 1.5). However, the significant values 
were found primarily in the comprehensive regimen grouping. This may have been a result of 
smaller insignificant associations coalescing into significance. Regardless of reasoning, this 
study was intended to open new avenues of investigation rather than concretely describe 
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relationships. As some of the polymorphisms presented with relatively large effects on respective 
levels, these may need to be examined further. Secondly, there were many SNP associations 
found with BUN levels (Table 1.6) with primarily minor effects and the three SNPs in the 
comprehensive group seemed to improve renal function as measured by eGFR (Table 1.7). 
Elvitegravir grouping found SNP associations with lower eGFR. As noted earlier the presence of 
cobicistat and tenofovir may have contributed to these outcomes (D. E. Murrell et al., 2015).     
Thirdly, several SNP associations were found across CNS (Table 2.1) and GI (Table 2.2) 
event occurrence. Abnormal dreams associations may have been associated with penetration of 
raltegravir into cerebrospinal fluid (Tsuchiya et al., 2014). Our results also indicate that, overall, 
anxiety occurred across the tested INSTIs. Drug transportation may help to explain the abnormal 
dreams and anxiety as changes were seen when alleles changed in some SNPs. Fatigue also had 
associations, but the variations were large when considering raltegravir grouping. Headache 
prediction was also possible; however, the high variation lessens the strength of the result. 
Insomnia, diarrhea, and nausea occurrence had associated SNPs; however, as with the other 
associations the mechanisms are unclear. 
As noted in Chapters 2 and 3, this study has limitations. The first being the low sample 
size, in terms of regimen group size and the occurrence of different alleles, which may have 
influenced study outcomes. A case-control study design may be more helpful in the future. 
Another limitation is that SNPs that occur more in different people groups may have been missed 
in this relatively homogenous population. A third limitation is the adverse event recording 
method. Our method did not take into account alternative explanations and were not evaluated 
for relatedness by a physician.  
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In conclusion, we determined some patient outcomes were associated with several SNPs. 
The fact that many have been previously unreported may be related to perceived clinical 
significance; however, our results add to the understanding of possibly related factors. 
Additionally, we found that raltegravir may need to be monitored in terms of abnormal dreams. 
As INSTIs are frontline regimens, information which may inform regimen choices is important 
for the prescribing physician as well as the patient. 
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APPENDIX 
SUPPLEMENTARY TABLES 
 
 
 
Regimen SNP Allele 
Abnormal dream 
occurrence 
No Yes 
ALL rs1143672 (A>G) AA 19 6 
  GA 36 6 
  GG 21 0 
Raltegravir rs1128503 (C>T) CC 4 4 
  CT 10 3 
  TT 2 0 
 
Table S1: Abnormal dream occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Anxiety  
occurrence 
No Yes 
ALL rs1143672 (G>A) GG 16 5 
  GA 34 8 
  AA 12 13 
 rs9934438 (G>A) GG 33 9 
  GA 24 12 
   AA 5 5 
 rs9923231 (C>T) CC 33 9 
  CT 24 12 
   TT 5 5 
 
Table S2: Anxiety occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Fatigue  
occurrence 
No Yes 
ALL rs1128503 (C>T) CC 19 16 
  CT 30 13 
   TT 10 0 
 rs2070673 (T>A) TT 41 14 
  TA 17 12 
    AA 1 3 
 rs1902023 (G>T) GG 20 6 
  GT 27 10 
   TT 12 13 
Raltegravir rs3892097 (G>A) GG 13 3 
  GA 2 5 
   AA 0 0 
 rs1065852 (C>T) CC 13 3 
  CT 2 4 
   TT 0 1 
 rs316019 (G>T) GG 14 4 
  GT 1 4 
   TT 0 0 
 
Table S3: Fatigue occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Headache  
occurrence 
No Yes 
ALL rs1695 (A>G) AA 32 5 
  AG 32 9 
   GG 4 6 
 rs2306283 (G>A) GG 18 4 
  GA 36 4 
   AA 14 12 
 rs3213619 (T>C) TT 66 17 
  TC 2 3 
  CC 0 0 
 
Table S4: Headache occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Insomnia 
occurrence 
No Yes 
ALL rs9934438 (G>A) GG 38 4 
  GA 26 10 
   AA 7 3 
 rs9923231 (C>T) CC 38 4 
  CT 26 10 
   TT 7 3 
 
Table S5: Insomnia occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Diarrhea 
occurrence 
No Yes 
ALL rs4680 (A>G) AA 15 13 
  AG 29 11 
   GG 18 2 
 
Table S6: Diarrhea occurrence in associated SNPs by allele 
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Regimen SNP Allele 
Nausea  
occurrence 
No Yes 
ALL rs1695 (A>G) AA 33 4 
  AG 33 8 
  GG 6 4 
 rs1208 (A>G) AA 31 3 
  AG 30 8 
  GG 11 5 
 
Table S7: Nausea occurrence in associated SNPs by allele 
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